Summary:
1. Dividend stocks offer passive income, but high yields can raise concerns.
2. Pfizer’s acquisitions and dividend track record make it a strong investment.
3. Verizon’s strategic changes and consistent dividend make it an attractive option.
Rewritten Article:
Investing in dividend stocks is a smart way to generate passive income, but it’s important to be wary of high yields that may signal underlying issues. Two mega-dividend stocks with yields as high as 7% are Pfizer and Verizon.
Pfizer, a leading U.S. drugmaker, recently made a significant move by acquiring Seagen for $43 billion to strengthen its oncology pipeline. This strategic acquisition is expected to contribute $10 billion in adjusted revenue by 2030, offsetting potential revenue loss from expiring patents on exclusive drugs. Pfizer has also invested in weight-loss drugs and received a three-year exemption from pharma-specific tariffs in exchange for a $70 billion investment in U.S. manufacturing and research. With a solid track record of paying and increasing dividends for 16 consecutive years, Pfizer offers an impressive yield of over 7%.
Verizon, a major telecommunications company, is undergoing a strategic overhaul with the appointment of Dan Schulman, former CEO of PayPal, as the new CEO. Despite challenges in expanding its subscriber base, Verizon remains committed to improving customer satisfaction. The company has maintained its dividend for 19 years and boasts a yield of 6.8%, supported by a 12-month trailing free cash flow yield of nearly 11.5%. Despite recent stock performance, Verizon’s dividend remains stable and attractive for investors.
In conclusion, both Pfizer and Verizon offer compelling investment opportunities for those seeking reliable passive income through dividend stocks. Their strategic initiatives and consistent dividend payments make them strong contenders in the market.
